Success Stories: Postdoctoral Fellow in Internal Medicine in Louisiana Receives EB-2 NIW Approval
Client’s Testimonial:
Many thanks for all your help and collaboration.
Country of Origin: Iran
Service Center: Texas Service Center (TSC)
State of Residence at the Time of Filing: Louisiana
Approval Notice Date: January 27, 2014
Processing Time: 4 Months, 21 Days (including RFE response time)
North America Immigration Law Group – WeGreened.comrepresented a postdoctoral fellow in the field of Internal Medicine. This client’s research had included hemodialysis, diabetic nephropathy, cutaneous leishmaniasis, restless leg syndrome, acute kidney rejection, and the prevention of scars. The client had published his research in 42 articles, in addition to presenting his findings at 26 international conferences. At the time that his case was filed, the client’s work had been cited 107 times by researchers in his fieldindicating the global significance of his research work. One independent recommender explained: “Although this research holds significant value by enabling the development of new forms of treatment for diabetic nephropathy, [Client’s] research is also critical in reducing treatment costs and improving the quality of life of diabetic patients. Currently, the economic stress derived from the treatment of diabetic nephropathy is exceptionally significant, but in order to grasp its significance, the costs of related diseases must be taken into account. In 2008 alone, more than 200,000 people in the United States were diagnosed with end-stage renal disease directly resulting from diabetic nephropathy. During each of the last 10 years, the United States has spent approximately 15-20 billion dollars on the treatment of diabetic nephropathy. Additionally, it is estimated that if current diabetic trends continue, in the next 30-40 years 30% of all Americans will have diabetes. Of this 30%, l/3rd will suffer from diabetic nephropathy. Thus, improvements associated with arresting the progression of nephropathy associated with diabetes, a contributor to currently 44% of all nephropathy cases in the United States, will be highly significant.” This EB-2 NIW petition was approved in 4 months, 21 days, including the time taken to respond to an issued RFE.